share_log

Altamira Therapeutics | CORRESP: CORRESP

Altamira Therapeutics | CORRESP: CORRESP

Altamira Therapeutics | CORRESP:信函
美股sec公告 ·  04/16 12:50
Moomoo AI 已提取核心訊息
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-1 effective by 4:00 p.m. Eastern Time on April 17, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. The company's CEO, Thomas Meyer, signed the request, which was facilitated by Alex Dinur of Lowenstein Sandler LLP. Altamira Therapeutics is awaiting confirmation from the SEC for the effectiveness of their Registration Statement, which is a critical step in the process of a public offering.
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-1 effective by 4:00 p.m. Eastern Time on April 17, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. The company's CEO, Thomas Meyer, signed the request, which was facilitated by Alex Dinur of Lowenstein Sandler LLP. Altamira Therapeutics is awaiting confirmation from the SEC for the effectiveness of their Registration Statement, which is a critical step in the process of a public offering.
Altamira Therapeutics Ltd.已正式要求美國證券交易委員會(SEC)宣佈其F-1表格的註冊聲明在東部時間2024年4月17日下午4點之前生效。該請求是根據1933年《證券法》第461條提出的,是通過EDGAR提交的信函提交的。該公司首席執行官托馬斯·邁耶簽署了該請求,洛文斯坦·桑德勒律師事務所的亞歷克斯·迪努爾爲該請求提供了便利。Altamira Therapeutics正在等待美國證券交易委員會確認其註冊聲明的有效性,這是公開募股過程中的關鍵一步。
Altamira Therapeutics Ltd.已正式要求美國證券交易委員會(SEC)宣佈其F-1表格的註冊聲明在東部時間2024年4月17日下午4點之前生效。該請求是根據1933年《證券法》第461條提出的,是通過EDGAR提交的信函提交的。該公司首席執行官托馬斯·邁耶簽署了該請求,洛文斯坦·桑德勒律師事務所的亞歷克斯·迪努爾爲該請求提供了便利。Altamira Therapeutics正在等待美國證券交易委員會確認其註冊聲明的有效性,這是公開募股過程中的關鍵一步。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息